Elanco Animal Health (ELAN) AI Stock Analysis

• Market Cap: $13.13B
• Dividend Yield: N/A
• Average Volume (3M): 4.44M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: 3.08%
• EPS Growth: -82.39%
• Country: US
• Employees: 9,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.13
• Shares Outstanding: 497,168,100
• 10 Day Avg. Volume: 4,708,247
• 30 Day Avg. Volume: 4,437,452
• PEG Ratio: 0.29
• Price to Book (P/B): 1.72
• Price to Sales (P/S): 2.38
• P/FCF Ratio: 39.55
• Enterprise Value/Market Cap: 1.25
• Enterprise Value/Revenue: 3.49
• Enterprise Value/Gross Profit: 7.50
• Enterprise Value/Ebitda: 22.76
• 1Y Price Target: $28.91
• Price Target Upside: 9.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): 1.03
• Revenue Forecast (FY): $4.98B

• Rating: 64 Neutral
• Price Target: $28.00 ▲(6.06% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

ELAN scores moderately, led by a positive earnings outlook (raised innovation expectations and higher 2026 EBITDA/EPS guidance) and strong technical uptrend (price above key moving averages with positive MACD). Financials are mixed—cash flow and leverage trends help, but profitability remains inconsistent with a 2025 net loss. Valuation is a notable drag due to the negative P/E and lack of dividend support.

Positive Factors

Innovation revenue ramp

Elanco’s sizable and accelerating innovation revenue demonstrates structural product-led growth rather than one-off gains. Raising innovation guidance to $1.15B reflects scalable launch execution and R&D productivity, supporting multi-year revenue expansion and stronger mix/ margins as new blockbusters scale globally.

Portfolio & share gains across pets and farm

Broad product momentum across companion and food-animal categories signals durable market position and cross-sell leverage. Rapid clinic penetration for Credelio Quattro and ZENRELIA share gains suggest sustainable adoption, higher reorder rates, and long-term TAM capture rather than transient demand spikes.

Solid cash generation and deleveraging path

Consistent operating cash flow and positive free cash flow in 2025 provide durable funding for launches, R&D and debt reduction. Management targets sub‑3x leverage with clear milestones; improving cash conversion enhances financial flexibility and reduces refinancing and interest-rate vulnerability over the medium term.

Negative Factors

Profitability volatility

Elanco’s inconsistent profitability and swings to net losses constrain long-term capital efficiency and returns. Volatile net margins create uncertainty around sustainable ROE, make planning for dividends or buybacks harder, and increase sensitivity to margin pressure from inflation or pricing competition.

Manufacturing ramp constraints for biologics

Scaling monoclonal antibody production is capital- and time-intensive; phased launches due to bioreactor constraints can delay revenue realization and limit margin expansion. Persistent capacity bottlenecks risk slower market penetration of high-value launches and increase execution risk over multiple quarters.

Elevated leverage and rising interest costs

Although leverage is improving, a 3.6x net leverage level and higher interest costs reduce strategic flexibility and increase vulnerability to macro shocks. Elevated debt hampers ability to fund larger M&A or invest aggressively, and interest expense headwinds can materially weigh on adjusted earnings if cash generation weakens.

Elanco Animal Health Business Overview & Revenue Model

Company Description

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

How the Company Makes Money

Elanco Animal Health generates revenue primarily through the sale of its animal health products, including prescription pharmaceuticals, over-the-counter medications, vaccines, and nutritional supplements. The company has a diversified revenue model that includes direct sales to veterinarians, livestock producers, and distributors. Key revenue streams come from its established portfolio of products, which address various health challenges in both companion and food animals. Additionally, Elanco benefits from strategic partnerships and collaborations with other companies and research institutions to enhance its product offerings and expand its market reach. The company's focus on innovation and developing new products, as well as its global presence, contributes significantly to its earnings.

Elanco Animal Health Financial Statement Overview

Summary

Cash generation is the strongest element (positive operating cash flow in 2024–2025 and positive 2025 free cash flow despite a net loss), and leverage is trending better (debt-to-equity improved to ~0.61). Offsetting this, revenue has been mostly flat with only a modest 2025 pickup, and profitability/ROE are inconsistent with a return to a net loss in 2025.

Income Statement

Revenue has been relatively flat over the past several years, with a modest pickup in 2025 (annual revenue up to ~$4.7B). Profitability is volatile: the company swung from a solid profit in 2024 (positive net margin) back to a loss in 2025 (negative net margin), and it also posted a large loss in 2023. A clear positive is the sharp improvement in gross margin in 2025 versus prior years, but bottom-line consistency remains the key weakness.

Balance Sheet

Leverage looks manageable but meaningful: debt-to-equity improved to ~0.61 in 2025 from higher levels in 2023–2024, suggesting some balance sheet de-risking. Equity remains sizable relative to assets, but returns to shareholders are inconsistent, with negative return on equity in 2025 (following a positive 2024). Overall, the balance sheet is improving on leverage, but profitability-driven capital efficiency is still a risk.

Cash Flow

Cash generation is a relative strength: operating cash flow remained solid in 2024–2025 (~$0.54–$0.56B) and free cash flow stayed positive in 2025 (~$0.28B) despite the reported net loss. However, free cash flow declined materially in 2025 versus 2024 (negative growth), and cash conversion versus earnings is not consistently strong across years, highlighting some underlying volatility.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.71B	4.44B	4.42B	4.41B	4.76B
Gross Profit	2.05B	1.91B	1.94B	1.97B	2.08B
EBITDA	676.00M	1.49B	-224.00M	866.00M	409.00M
Net Income	-232.00M	338.00M	-1.23B	-78.00M	-483.00M
Balance Sheet
Total Assets	13.36B	12.61B	14.36B	15.49B	16.48B
Cash, Cash Equivalents and Short-Term Investments	545.00M	468.00M	352.00M	345.00M	638.00M
Total Debt	4.02B	4.32B	5.77B	5.84B	6.32B
Total Liabilities	6.81B	6.52B	8.14B	8.20B	8.97B
Stockholders Equity	6.55B	6.10B	6.22B	7.29B	7.51B
Cash Flow
Free Cash Flow	284.00M	394.00M	117.00M	268.00M	286.00M
Operating Cash Flow	560.00M	541.00M	271.00M	452.00M	483.00M
Investing Cash Flow	-279.00M	1.16B	-169.00M	-179.00M	-530.00M
Financing Cash Flow	-275.00M	-1.49B	-83.00M	-549.00M	210.00M

Elanco Animal Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELAN, the sentiment is Positive. The current price of 26.4 is above the 20-day moving average (MA) of 25.18, above the 50-day MA of 24.12, and above the 200-day MA of 19.35, indicating a bullish trend. The MACD of 0.59 indicates Negative momentum. The RSI at 62.07 is Neutral, neither overbought nor oversold. The STOCH value of 70.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELAN.

Elanco Animal Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZTS	75 Outperform	$55.34B	21.77	65.99%	1.69%	2.68%	11.51%
PAHC	74 Outperform	$2.22B	24.20	31.80%	1.28%	33.71%	289.48%
RDY	70 Outperform	$11.77B	18.45	―	0.64%	10.63%	6.35%
ELAN	64 Neutral	$13.13B	―	-3.67%	―	3.08%	-82.39%
TEVA	63 Neutral	$39.41B	27.82	21.37%	―	-0.25%	―
VTRS	56 Neutral	$17.19B	-5.04	-21.08%	3.99%	-6.40%	-320.23%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Elanco Animal Health Corporate Events

Elanco Animal Health Announces Restructuring Plan for Growth

On December 5, 2025, Elanco Animal Health‘s Board of Directors authorized a restructuring plan to enhance margin expansion, optimize its global footprint, and invest in innovation. This plan includes a global headcount reduction and relocation of positions, with expected pretax charges of $175 million. The company also announced its financial outlook and innovation strategy at its 2025 Investor Day, highlighting a three-year growth plan starting in 2026, driven by innovation and strategic investments in U.S. operations. Elanco aims to achieve significant revenue growth from new products and maintain leadership in the animal health market.

The most recent analyst rating on (ELAN) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Elanco Animal Health stock, see the ELAN Stock Forecast page.